Equity Overview
Price & Market Data
Price: $1.76
Daily Change: -$0.19 / 10.80%
Daily Range: $1.75 - $2.08
Market Cap: $21,833,704
Daily Volume: 154,894
Performance Metrics
1 Week: -19.37%
1 Month: 18.54%
3 Months: 14.01%
6 Months: -46.73%
1 Year: -95.30%
YTD: -47.97%
Company Details
Employees: 42
Sector: Health technology
Industry: Biotechnology
Country:
Details
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.